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The prevalence of overt and subclinical hypothyroidism during pregnancy is estimated to be 0.3–0.5% and 2–3%, respectively.
Thyroid autoantibodies are found in 5–18% of women in the childbearing age. The aim of this review is to underscore the clinical
signiﬁcance of these ﬁndings on the health of both the mother and her oﬀspring. Methods of evaluation of thyroid function
tests (TFTs) during pregnancy are described as are the threshold values for the diagnosis of overt and subclinical hypothyroidism
or hypothyroxinemia. Anticipated diﬀerences in TFTs in iodine-suﬃcient and iodine-deﬁcient areas are discussed and data are
provided on potential complications of hypothyroidism/hypothyroxinemia and autoimmune thyroid disease during pregnancy
and adverse eﬀects for the oﬀspring. The beneﬁcial eﬀects of levothyroxine therapy on pregnancy outcomes and oﬀspring
development are discussed with a proposed treatment regimen and follow up strategy.
1.Introduction
During normal gestation, thyroid hormone production
is augmented in order to meet the increased physiologic
demands of the growing fetal placental unit. Alterations
in thyroid function with pregnancy are derived via several
mechanisms. Notably, there is an increase in serum estrogen
levelsduringtheﬁrsthalfofgestationupto500–1000pg/mL,
resulting in upregulation by two- or threefold of hepatic
production of thyroxine binding globulin (TBG) [1, 2]. The
increased TBG levels alter the equilibrium between bound
and free thyroxine (FT4) causing a temporary reduction
in FT4 that in turn leads to increased thyrotropin (TSH)
stimulation of the thyroid gland and physiologic restoration
of FT4 at the cost of higher serum total T4 (TT4) levels.
A second factor is the increased placental production of
human chorionic gonadotropin (hCG), reaching a peak of
approximately 50,000–75,000IU/L at 8–11 weeks. This is
signiﬁcant because of the direct stimulatory eﬀect of hCG
on thyrocytes that is mediated through binding to the TSH
receptor. Yet a third issue is related to the increased need for
iodine in pregnancy that is required to fuel the increases in
thyroid hormone synthesis and compounded by the loss of
iodine due to enhanced renal clearance [3, 4]. Therefore, the
recommended average iodine intake during the pregnancy
is between 250 and 500 ug/d [5, 6] .Aﬁ n a lf a c t o ri st h e
presence of placental iodothyronine deiodinase type III
which alters the metabolism, distribution, and availability of
T4 for both mother and fetus [4].
The prevalence of hypothyroidism during pregnancy is
estimated to be 0.3–0.5% for overt hypothyroidism (OH)
and 2-3% for subclinical hypothyroidism (SH). Thyroid
autoantibodies are found in 5–18% of women in the child-
bearing age, and chronic autoimmune thyroiditis (AITD)
is the main cause of hypothyroidism during pregnancy in
iodide suﬃcient areas [7–9]. However, on a worldwide basis
the most important cause of thyroid insuﬃciency remains
iodine deﬁciency [10].
In view of the frequency of either OH or SH during
pregnancy and the associated altered physiology, several
questions face clinicians managing subjects with suspected
thyroid dysfunction during pregnancy including (1) what2 Journal of Thyroid Research
are the threshold values for the diagnosis of overt hypothy-
roidism(OH),subclinicalhypothyroidism(SH),orhypothy-
roxinemia during the pregnancy? (2) Is the interpretation
of thyroid function tests diﬀerent in iodine-suﬃcient than
in iodine-deﬁcient areas? (3) What are the complications
of hypothyroidism/hypothyroxinemia and autoimmune thy-
roid disease during the pregnancy? (4) Is levothyroxine
therapy beneﬁcial and eﬀective in regard to improved out-
comes and reduced complications associated with pregnancy
and delivery? (5) How to select the patients for whom the
treatment may be beneﬁcial? (6) What is the appropriate
treatment regimen and what are target thyroid function test
values and how often should they be monitored? The aim of
this paper is to address all of the above mentioned questions.
2. Methods
We have searched PubMed database from January 1970
to January 2011 for the articles written in English using
the following keywords: “pregnancy and thyroid function”,
“pregnancy and hypothyroidism”, “pregnancy and subclin-
ical hypothyroidism”, “pregnancy and hypothyroxinemia”,
“pregnancy and levothyroxine treatment”, “pregnancy and
iodine deﬁciency”, “oﬀspring complications and hypothy-
roidism”, “oﬀspring complications and hypothyroxinemia”
and“oﬀspringcomplicationsandiodinedeﬁciency”.Wehave
included retrospective and prospective observational studies,
clinical trials, meta-analyses, review papers, and guidelines
published in the indexed journals.
2.1. What are the Threshold Values for the Diagnosis of Overt
Hypothyroidism (OH), Subclinical Hypothyroidism (SH),
or Hypothyroxinemia during the Pregnancy?
Establishment of reference ranges for thyroid function tests
during pregnancy has been problematic due to variables
based upon age, smoking status, ethnicity, BMI, iodine
nutritional status, and the presence of latent or overt
autoimmune thyroid disease [8, 11].
Interpretation of any given value for FT4 or TSH should
take into account the possible diﬀerences between popula-
tion based reference ranges of thyroid function tests and a
given patient’s narrower individual reference range. Based
on data from 877 pregnant women, Shields et al. suggested
that an individual’s level of TSH is associated with variation
in the PDE8B gene with AA genotypic women being more
likely to have elevated TSH concentrations (>4.21mIU/L)
compared to women with AG or GG genotypes (9.6 versus
3.5%, P<0.0004). This observation was independent of the
presence or absence of autoimmune thyroid disease (AITD)
[12].
2.1.1. Normal Absolute Values and Optimal Methods for
Assessment of Thyroid Function during Pregnancy
TSH. TSH is the single best indicator of insuﬃcient thyroid
hormone due to primary hypothyroidism [6]. However,
there is a necessity for the trimester-speciﬁc reference range
for TSH in each laboratory or at least each country/region in
order to properly interpret the thyroid function tests.
Guidelines for diagnosis developed by the Endocrine
Society and endorsed by the American Thyroid Association
in 2007 recommend that TSH values should be <2.5mIU/L
in the ﬁrst trimester and <3mIU/L in the second and
third trimester [6]. Data supporting this recommendation
were derived from observations of the consistency in TSH
ranges for ﬁrst-trimester thyroperoxidase antibody-negative
women, with a consensus centering around a lower limit of
normal of 0.04 and upper range of normal of 2.5mIU/L.
It is worthwhile to underscore that this reference range was
not signiﬁcantly diﬀerent between various populations. In a
prospective study of 343 Chinese women, Panesar et al. [13]
noted a normative range for ﬁrst-trimester TSH levels of
0.03–2.3mIU/L, which did not diﬀer signiﬁcantly from the
range of 0.02–2.15mIU/L established by Gilbert et al. [14]i n
1817 Australian women between 9 and 13 weeks of gestation.
A somewhat wider range and higher upper limit was seen by
Pearce et al. [15] of 0.04–3.6mIU/L in 585 thyroid antibody-
negative women before 14 wks gestation, and by Stricker
et al. [16] after screening 783 thyroid antibody-negative
women in Switzerland (TSH 0.08–2.83mIU/L). M¨ annist¨ oe t
al. based on a large (n = 9362) prospective population-based
cohort from Northern Finland without AITD and with
suﬃcient iodine intake reported a TSH reference range of
0.07 to 3.1 in the ﬁrst trimester and up to 3.5mIU/L in the
second trimester. Moreover, they also observed that thyroid
hormone levels are aﬀected by BMI with higher TSH and
FT3 and lower FT4 concentrations observed in obese women
[11].
FT4, FT3. Although equilibrium dialysis and mass spec-
trometry/gas chromatography are the gold standards and
are the most reliable methods of measurement of both FT4
and FT3 concentrations, these methods are too technically
complex and expensive for routine use. Consequently, most
FT4 testing in clinical laboratories is based on two-step
or labeled antibody methodology, which is sensitive to
abnormal TBG levels and liable to error [17, 18] .T h e r ei sa
need for a method-speciﬁc, trimester-speciﬁc, and possibly
population-speciﬁc FT4 reference range. M¨ annist¨ oe ta l .
addressed this question for the anti-TPO negative and iodine
suﬃcient Caucasian population, documenting that FT4
measured with chemiluminescent immunoassay increases
slightly during early pregnancy and then decreases with the
reference ranging being between 11 and 22pmol/L. Refer-
ence intervals for FT3 in the same study were stable during
the pregnancy and ranged from 3.4 to 7pmol/L [11]. How-
ever, Lee et al. documented that FT4 measured by two diﬀer-
ent immunometric assays diverges so signiﬁcantly during the
second and third trimesters that the vast majority of women
would be diagnosed incorrectly as hypothyroxinemic by
laboratory criteria alone. Each speciﬁc immunoassay needs
to have normals and abnormals determined for the pregnant
state, or immunoassays may underestimate FT4 [19].
TT4. The TT4 increase in pregnancy is more predict-
able than alterations in FT4, being generally 1.5 timesJournal of Thyroid Research 3
nonpregnant levels which is primarily related to increases
in serum TBG as described above. Many studies have
shown remarkably consistent ranges for T4 throughout
pregnancy—approximately 143–158% of nonpregnant val-
ues. Adjusting the TT4 in pregnancy by a factor of 1.5 com-
pared with nonpregnant reference ranges is a good reﬂection
ofFT4[19].Therefore,someauthorsadvocatetheuseofTT4
in preference to FT4 for the evaluation and management of
pregnant patients [20]. The Endocrine Society Guidelines as
well as Laboratory Medicine Practice Guidelines advocate a
TT4 cutoﬀ of 100nmol/L as appropriate for detecting a low
FT4 state in pregnancy [6, 20].
FT4 Index. The free thyroxine index (FT4I) is measured
as total T4 mathematically corrected for thyroxine binding
globulin (TBG). FT4I is calculated by dividing TT4 by
the thyroid hormone-binding ratio—the estimate of TBG.
Changes in FT4I are consistent with the expected eﬀects of
TBG and hCG during pregnancy with a physiologic increase
in the ﬁrst trimester with normalization to nonpregnant
levels in the second and third trimesters. This pattern of
change during pregnancy corresponds to that described
using the gold standard FT4 methods of equilibrium dialysis
and tandem mass spectrometry [19].
To summarize, the FT4I index or the TT4 adjusted for
pregnancy are reliable methods of estimating free thyroxine
status in pregnancy.
2.2. Is the Interpretation of Thyroid Function Tests Diﬀerent in
Iodine-Suﬃc i e n tt h a ni nI o d i n e - D e ﬁ c i e n tA r e a s ?
Approximately 1.9 billion individuals, including 285 mil-
lion school-aged children, are estimated to have inade-
quate iodine nutrition. Severe iodine deﬁciency in preg-
nancy can cause hypothyroidism, poor pregnancy outcome,
cretinism, and irreversible mental retardation. Mild-to-
moderate iodine deﬁciency in utero and in childhood may
result in less severe learning disability, poor growth, and
diﬀuse goiter [21]. It has been also suggested that even mild
iodinedeﬁciencymaybeassociatedwithattentiondeﬁcitand
hyperactivity disorders in oﬀspring [22].
The prevalence of iodine deﬁciency is lowest in the
Americas (10.1%) and highest in Europe (59.9%) [23].
The thyroid gland responds to iodine deﬁciency through
regulatory mechanisms that include decreased synthesis and
secretionofT4infavorofT3.Inthecaseofmildtomoderate
iodine deﬁciency during the pregnancy, the circulating T3
levelsremainnormal orevenincreaseslightly andcirculating
TSH levels do not increase. So the thyroid function tests may
misleadingly indicate euthyroidism, while the amount of T4
available for the fetus might be insuﬃcient [24, 25]. Another
commonly seen diagnostic marker of iodine deﬁciency is an
elevated serum thyroglobulin level [26]. Serum Tg is well
correlated with the severity of iodine deﬁciency as measured
by UI [27]. Intervention studies examining the potential of
Tg as an indicator of response to iodine supplementation
revealed that Tg falls rapidly with iodine repletion and that
Tg is a more sensitive indicator of iodine repletion than TSH
or T4 [28, 29].
Iodine repletion in severely iodine-deﬁcient pregnant
women or infants may reduce the infant mortality rate by
at least 50% [21]. A blinded, placebo-controlled clinical trial
conductedinthe1960sinPapua,NewGuinea,demonstrated
that preconception supplementation of severely iodine-
deﬁcient women with iodinated oil eliminated the risk
for cretinism and improved oﬀspring cognitive function
and survival [30]. These ﬁndings have subsequently been
replicated in many regions of the world, indicating that
iodine supplementation in severely iodine-deﬁcient regions
may increase the average child IQ by 12.5 points [31, 32].
Iodine supplementation of moderately deﬁcient preg-
nant women appears to consistently decrease maternal
and neonatal thyroid volumes and Tg levels [31]. Eﬀects
on maternal thyroid function have been variable, with
signiﬁcant maternal TSH decreases seen only in four of
eight published studies and with increases in maternal
T4 or FT4 noted in two studies [31]. The observed dif-
ferences in the response to iodine supplementation may
be related to the onset of intervention. In a prospective
observational study, Moleti et al. studied 433 euthyroid anti-
TPO antibody-negative women and observed TSH increases
during gestation in 26.1% women taking 150ug iodine
supplementation during the pregnancy compared to 15.6%
of women with a history of iodinated salt intake several
months before the pregnancy (P<0.05). However both
methods of iodine supplementation were suﬃcient to reduce
the proportion of pregnant women with hypothyroxinemia,
which was observed in 8.3% of women taking 150ug iodine
supplements, 9.5% of women with a history of iodine salt
use,and20%ofwomenwithoutanyiodinesupplementation
[33]. These observations were conﬁrmed in other studies
[34, 35]. Neurodevelopmental outcomes were improved in
children whose mothers received iodine supplementation
early in pregnancy and were lost if supplementation was
started after the 10th week of pregnancy [36, 37].
These results suggest that women from mildly and
moderately iodine-deﬁcient areas, which include several
Europeancountries,shouldbeadvisedtostartiodinesupple-
mentation several months prior to conception in order
to saturate intrathyroidal iodine stores. Ideally, women
should have adequate intrathyroidal iodine stores (10–
20mg) before conception. Unfortunately, well-conducted
randomized maternal iodine-supplementation studies with
long-term follow-up data on psychomotor and mental
development of children are lacking.
2.3. What are the Complications of Hypothyroidism/
Hypothyroxinemia and Autoimmune Thyroid Disease
during the Pregnancy?
2.3.1. Hypothyroidism
Pregnancy Complications. There is a known association
between hypothyroidism and decreased fertility, as well as
increased risk for early and late obstetrical complications,
such as increased prevalence of abortion, anemia, gestational
hypertension, placental abruption, and postpartum hemor-
rhages. As would be expected, these complications are more4 Journal of Thyroid Research
frequent with OH than with SH [38–43]. In one study of 216
women with early miscarriage, SH and AITD were indepen-
dently associated with miscarriage with SH being speciﬁcally
a s s o c i a t e dw i t hv e r ye a r l ye m b r y ol o s sa t6 . 5w e e k s[ 44]. In
contrast, a prospective study of 10,990 women in US and
IrelandwithbiochemicalevidenceofSHdidnotrevealexces-
sive adverse pregnancy outcomes [45]. Recent studies from
The Netherlands documented an association between TSH
levels exceeding >2.4mIU/mL between the 35th and 38th
week of gestation are associated with the approximately 2-
fold increased risk for breech presentation [46, 47]. Elevated
TSH levels earlier during the pregnancy were not associated
with risk of breech presentation. Interestingly, higher levels
of TSH at end term were independently associated with the
lack of successful outcome of external cephalic version [48].
Adverse Outcomes for the Neonate/Oﬀspring. Untreated
maternal OH is associated with adverse neonatal outcomes
including premature birth, low birth weight, and neonatal
respiratory distress. Although less frequent than with OH,
complications have also been described in newborns from
mothers with SH, including a doubling of the rate of preterm
delivery [49] in pregnant women before 20wk gestation.
Stagnaro-Green et al. [50] compared the thyroid status of
women with preterm delivery to matched controls who
deliveredattermandfounda3-foldincreaseintheincidence
ofSHinthewomenwithveryearlypretermdeliveries(before
32wks).
Four decades ago Man et al. [51, 52] observed that
childrenborntomotherswithinadequatelytreatedhypothy-
roidism had signiﬁcantly reduced intelligence quotients
(IQs). The ﬁrst large-scale prospective study on the outcome
of children born to mothers with SH during pregnancy was
reported by Haddow et al. in 1999 [53]. In this study, exten-
sive neuropsychological testing of the school-age children
revealed that children born to women with untreated SH
had on average an IQ score that was 7 points below the
mean IQ of children born to healthy women and thyroxine-
treatedwomen.Furthermore,therewerethreetimesasmany
childrenwithIQsthatwere2SDscoresbelowthemeanIQof
controls in the children born to untreated women with SH.
Ofnote,thereisaspeciﬁctypeofcombinedmaternaland
fetal hypothyroidism during gestation associated with the
presenceofTSHreceptorblockingantibodiesinwomenwith
AITD. This entity is associated with more severe cognitive
delay in the oﬀspring than seen with either fetal or maternal
hypothyroidism alone, probably because maternal T4 is
unavailable to compensate for the fetal hypothyroidism.
This disorder should be suspected if unusually high doses
of levothyroxine (LT4) are required to normalize maternal
thyroid function during gestation [54]. Additional studies
willberequiredtoelucidatetheeﬀectofSHonthelong-term
neuropsychological development of oﬀspring.
2.3.2. Isolated Hypothyroxinemia
Pregnancy Complications. Cleary-Goldman et al. showed
that isolated hypothyroxinemia,which was observed in 232
of 10,990 pregnant women, is not associated with adverse
pregnancy outcomes [45]. Similar observations were noted
by Casey et al. who observed hypothyroxinemia among 233
of 17,298 pregnant women. This was not associated with
any increased risk for adverse pregnancy outcomes in this
subpopulation [55].
Adverse Outcomes in Oﬀspring. Despite the limitations of
FT4 assays, multiple studies have demonstrated that low-
normal FT4 concentrations are associated with adverse
outcomesintheoﬀspring.Popetal.investigatedthedevelop-
mentaloutcomeinchildrenborntowomenwithisolatedlow
T4 levels in the ﬁrst trimester of pregnancy, deﬁned as values
within the lowest 10th decile of “normal” pregnant T4 values
[56]. Results suggested that isolated hypothyroxinemia is
associated with a lower developmental index in the children
at approximately 10 months of age. This observation was
conﬁrmed later by the same group based on a larger cohort
and more reﬁned motor and mental evaluations in infants
aged1and2yrs[57].Theydocumentedthatchildrenbornto
motherswithprolongedlevelsoflowT4(untilwk24orlater)
showed an 8- to 10-point deﬁcit for motor and mental devel-
opment compared to infants of women whose serum FT4
levels recovered spontaneously to normal later in gestation.
These results were conﬁrmed by Vermiglio et al. [22],
who compared the neuropsychological development of
children of mothers from a moderately iodine-deﬁcient
area to that of children of mothers from a marginally
iodine-suﬃcient area. The oﬀspring of the mothers with
lower FT4 values during gestation were found to have an
increased incidence of attention deﬁcit and hyperactivity
disorder as well as a reduced IQ, compared with controls.
Similarly, Kooistra et al. observed that newborns from
hypothyroxinemic mothers (FT4 below the 10th percentile
at 12th week of pregnancy), and evaluated 3 weeks after
delivery with the Neonatal Behavioural Assessment Scale,
had signiﬁcantly lower orientation index scores compared
to children whose mothers had FT4 levels between the 50th
and 90th percentiles [58]. Similar observation was found
in Chinese population, indicating that children of women
with either SH, hypothyroxinemia, or elevated TPO Ab
titres at 16–20 weeks gestation had mean intelligence and
motor scores signiﬁcantly lower than controls [59]. Finally, a
recent population-based cohort study from The Netherlands
involving 3659 children and their mothers documented that
both mild (below the 10th percentile) and severe (below
5 percentile) maternal hypothyroxinemias were associated
with a higher risk of expressive language delay at 18 and 30
months. Severe maternal hypothyroxinemia also predicted a
higher risk of nonverbal cognitive delay [60].
2.3.3. Euthyroid Autoimmune Thyroid Disease
Pregnancy Complications. Experimental studies on pregnant
mice have shown an increased rate of miscarriage after
immunization with Tg [61, 62] .S e v e r a ls t u d i e sh a v ea l s o
indicated an association in women between the presence
of AITD and an increased miscarriage rate and pretermJournal of Thyroid Research 5
delivery [63–65]. Three hypotheses have been proposed to
explainthisassociation:(1)thyroidantibodiesmayrepresent
a marker of a generalized autoimmune imbalance that
increases risk of miscarriage; (2) preexisting subtle thyroid
dysfunction due to AITD may worsen during pregnancy;
( 3 )b e c a u s ew o m e nw i t hA I T Dh a v eah i g h e rp r e v a l e n c eo f
infertility, they may be older than those without AITD and
thus be more prone to fetal loss. Women with AITD are
also more likely to suﬀer from postpartum thyroiditis and
postpartum depression [66–69].
Side Eﬀects in the Oﬀspring. As far as we could determine,
other than the one study cited above [59], there is no other
evidence that high maternal TPO Ab titers are associated
with a delayed neurologic development of the oﬀspring.
2.3.4. Euthyroid TPO Ab Negative Women with
TSH between 2.5 and 5mIU/L
Pregnancy Complications. Ah i g h e rr a t eo fs p o n t a n e o u s
pregnancy loss was observed in a study of 642 women with
serum TSH ranging between 2.5 and 5mIU/L in the ﬁrst
trimester than in 3481 women with TSH below 2.5 (6.1%
versus 3.6%, P = 0.006, resp.) [70].
2.4. Is Levothyroxine Therapy Beneﬁcial and Eﬀective in
regard to Improved Outcomes and Reduced Complications
Associated with Pregnancy and Delivery?
Based upon data in the study by Abalovich et al. [38]
focused on 150 pregnancy outcomes in 114 women who
had either OH (n = 52) or SH (n = 62) (Table 1),
Stagnaro-Greenanalyzedthepretermdeliveryrateofwomen
who were either adequately treated at conception (n =
99) or during pregnancy (n = 27) versus women who
were inadequately treated during pregnancy (n = 24). The
analysisrevealedasigniﬁcantlylowerpretermdeliveryrateof
1.6% after adequate treatment with L-T4 compared to a rate
of 12.5% in the group of inadequately treated women with
TSH > 4mIU/L during pregnancy (P<0.05) [74]. There is
also evidence that LT4 treatment can improve implantation
rate and live birth rate in infertile women with subclinical
hypothyroidism undergoing in vitro fertilization [75].
Rovet [76] investigated children up to the age of 5
born to women who, although having been treated for
hypothyroidism during pregnancy, received suboptimal LT4
dosage as indicated by mean TSH levels between 5 and
7mIU/liter. The children at preschool age were found
to have a mild reduction in global intelligence that was
inversely correlated with maternal TSH level during the third
trimester. No negative impact was noted on language, visual
spatial ability, ﬁne motor performance, or preschool ability.
Preliminary results of the “Controlled Antenatal Thyroid
Screening Study” (CATS) were presented in September 2010
during International Thyroid Congress [73] .T h eC A T St r i a l
was a prospective randomized study that screened 22,000
women within the 16th week of gestation for thyroid status
with TSH and FT4 measurements. Women with FT4 values
lower than the 2.5th percentile and/or TSH values above
the 97.5th percentile were randomly assigned into an inter-
vention group treated with LT4 or a control group without
intervention. Neuropsychological development assessed by
Wechsler Preschool and Primary Scale of Intelligence (WPPS
III) was performed in the oﬀspring of both groups at 3 years
of age. Primary outcomes consisted of the mean WPPS III
score and the percentage of oﬀspring with IQ of <85 points.
Aprimaryanalysisthatincludedanintentiontotreatanalysis
revealed no signiﬁcant diﬀerences. The secondary analysis
which excluded women who had been noncompliant with
LT4 treatment also revealed no diﬀerence in relative risk of
full-scale IQ being below 85 in the screened group compared
to the control group.
Asecondstudyispresentlyinprogressundertheauspices
of the NIH. Pregnancy screening was initiated in October
2006,andstudycompletionisanticipatedin2015.Thatstudy
will eventually comprise a total of 120,000 pregnant women,
recruited from an obstetrical US network of 14 institutions.
Women with SH or isolated hypothyroxinemia will be
randomized to placebo versus LT4 treatment to normalize
serum TSH in women with SH or to normalize serum FT4
inwomenwithisolatedhypothyroxinemia[77].Theprimary
outcome of the study will be intellectual function of children
at 5 years of age as measured by the WPPSI-III. The WPPSI-
III scores of progeny of treated women will be compared to
thechildrenofuntreatedwomen.Secondaryoutcomesofthe
study include assessment of fetal growth, rates of preterm
delivery, preeclampsia, placental abruption, stillbirth, and
development of postpartum thyroid dysfunction.
2.4.1. Euthyroid Women with AITD. Negro et al. published
the ﬁrst study focused on the possible beneﬁt of LT4
treatment of anti-TPO positive euthyroid women deﬁned
as having serum TSH within a range 0.27–4.2mIU/L [72].
Among984patientswhocompletedthestudy,therewere155
anti-TPO positive women randomized into an intervention
group (n = 57) treated with LT4 at their ﬁrst prenatal
visit performed at a median 10 weeks of gestation and
a no intervention group (n = 58). TPO Ab negative
women (n = 869) served as a normal control group.
This study importantly demonstrated salutary eﬀects of LT4
administration to both correct maternal thyroid dysfunction
and also decrease the rate of adverse obstetrical events
such as miscarriage and premature delivery, bringing their
prevalencedowntothoseofthecontrolpopulation(Table1).
Nostudyhasyetdemonstratedwhethersimilarbeneﬁtmight
be gained with LT4 therapy of TPO Ab negative women.
2.5. How to Select the Patients for Whom
t h eT r e a t m e n tM a yB eB e n e ﬁ c i a l ?
2.5.1. Screening for Thyroid Dysfunction during Pregnancy.
In view of the growing evidence that abnormal thyroid
function during pregnancy is associated with less optimal
outcomes that can be improved with LT4 treatment, the
question arises as to whether to screen in early pregnancy for
thyroid dysfunction. The 2007 Endocrine Society Guidelines6 Journal of Thyroid Research
Table 1: Intervention studies describing the eﬃcacy of LT4 treatment during pregnancy.
Study Design Material Intervention Target TSH Pregnancy
complications
Oﬀspring
complications
Abalovich
et al. [38]
Retrospective
study of
pregnant
women with
OH
TSH > 5mIU/L,
T4 < 4.5ug/dL
and SH TSH >
5mIU/L,
T4 normal
114 women
OH n = 52
SH n = 62
99 pregnancies
conceived under
euthyroidism,
51 under OH or
SH
Treatment with
LT4 before or
during pregnancy
as soon as OH or
SH was diagnosed
Optimal treatment
TSH < 4mIU/mL
Inadequate
treatment
TSH > 4mIU/L
Among pregnancies
conceived under OH
or SH
miscarriage rate
inadequate versus
adequate treated 60%
versus 0% in OH and
71.4% versus 0% in
SH
Among pregnancies
conceived under OH
or SH
preterm deliveries
rate inadequate versus
adequate treated 20%
versus 0% in OH and
7.2% versus 9.5% in
SH
Hallengren
et al. [71]
Prospective
observational
63 pregnant
women with
OH treated with
LT4
Adjustment of the
LT4 dose <2mIU/L
Fetal loss 6% (2/32)
of optimally treated
patients versus 29%
(9/31) of women
treated inadequately
Not examined
Negro et al.
[72]
Prospective
randomized
trial
984 euthyroid
women with
TSH levels
<4.2mIU/L
group A, n = 57
TPO Ab (+)
women treated
with LT4 initiated
at median 10 weeks
of gestation versus
group B, n = 58
no treatment for
TPO Ab (+)
women versus
groups C n = 869
control TPO Ab
(−)
Dose of LT4 stable
during pregnancy
0.5ug/kg/d for
TSH < 1.0mIU/L
0.75ug/kg/d TSH
1.0-2.0mIU/L,
1ug/kg/d
TSH > 2.0mIU/L
or anti-TPO >
1500kIU/L
The rate of
miscarriage lower in
intervention group A
compared to group B
(3.5% versus 13.8%,
P<0.05) and similar
to controls (3.5%
versus 2.4%, P = ns)
Not examined
CATS study
Lazarus [73]
Prospective
randomized
trial
22,000 women
within the 16th
week of
gestation
In the intervention
group LT4 was
initiated during
pregnancy in
women with FT4
values lower than
the 2.5th percentile
and/or TSH values
above the 97.5th
percentile. The
control group
received no
intervention.
<2.5mIU/L I
trimester
<3mIU/L II and
III trimester
No data
The primary outcome
was the mean
WPPS-III score and
the percentage of
oﬀspring with IQ <
85 points. The
primary intention to
treat analysis revealed
no signiﬁcant
diﬀerences. A
secondary analysis
excluded women
noncompliant with
LT4 and also revealed
no diﬀerence in
relative risk of full
scale IQ being below
85 in the screen group
compared to the
control group.
[6] recommend case ﬁnding by measurement of TSH in
women in any of the following categories:
(1) personal history of abnormal thyroid function,
(2) family history of thyroid disease,
(3) goiter,
(4) positive thyroid antibodies,
(5) symptoms or clinical signs suggestive of thyroid
dysfunction,Journal of Thyroid Research 7
(6) type 1 diabetes,
(7) other autoimmune disorders,
(8) infertility,
(9) history of therapeutic head or neck irradiation,
(10) history of miscarriage or preterm delivery.
However, it has been suggested that we might fail
to detect 30% of hypothyroid and 69% of hyperthyroid
women if only high-risk pregnant women are screened
[78]. This argument is supported by demonstrating that
screening a low-risk group identiﬁed both hypothyroidism
and hyperthyroidism and allowed early therapy that resulted
in a lower rate of adverse obstetrical and fetal outcomes [79].
While a major argument against screening is the associated
cost of TSH measurements, it has been demonstrated that
screening pregnant women with TSH in the ﬁrst trimester
of pregnancy is cost-saving compared with no screening and
screening by measurement of anti-TPO antibodies is also an
economically favorable screening strategy [80].
2.6. What is the Appropriate Treatment Regimen;
What are Target Thyroid Function Test Values, and
How Often Should They Be Monitored?
Once a diagnosis of either OH or SH is made during
pregnancy, the Guidelines of the Endocrine Society clearly
recommend initiation of treatment with LT4 [6].
“LT4doseoftenneedstobeincrementedby4–6wk
gestation and may require a 30–50% increment
in dosage. If overt hypothyroidism is diagnosed
during pregnancy, thyroid function tests should
be normalized as rapidly as possible. The target
threshold TSH should be less than 2.5mIU/L in
the ﬁrst trimester and less than 3mIU/L in second
and third trimesters or to trimester-speciﬁc nor-
mal TSH ranges. Thyroid function tests should be
remeasured within 30–40d. After delivery, most
hypothyroidwomenneedtodecreasethethyroxine
dosage they received during pregnancy.”[6]
Notwithstanding the data extant demonstrating eﬃcacy
of LT4 therapy in preventing adverse pregnancy and oﬀ-
spring outcomes and the availability of published guidelines
addressing the treatment strategy, there is evidence that 24–
49% of women treated with LT4 before conception still
have elevated TSH levels at their ﬁrst prenatal visit [71, 81,
82]. The reasons for this are not clear but could include
failure to appreciate and recognize that dosage requirements
for LT4 may change with pregnancy as well as perhaps
f a i l u r et or e m e a s u r eT S Ha ts u ﬃciently frequent intervals.
In women already taking LT4, the magnitude of increase in
LT4 requirements with pregnancy is approximately 40–50%
of the prepregnancy dosage in athyreotic patients and about
20–30%forpatientswithunderlyingHashimoto’sthyroiditis
[6, 83–89]. The diﬀerence is due to the fact that the latter
patients typically will have some residual functioning mass
of thyroid tissue capable of releasing T4 that complements
the daily exogenous LT4 dose.
Because of the potential for clinicians to fail to identify
the demand for an increased LT4 dosage in pregnancy,
several studies have aimed to identify a practical therapeutic
approach to address this issue [90]. Rotondi et al. [91]
pointed out that the intervention should be made precon-
ception. They prospectively examined 25 women with com-
pensated hypothyroidism of diﬀerent etiology anticipating
pregnancy and assigned them to two groups: 14 patients had
their LT4 dose increased to a partially suppressive dose, while
11 patients continued the same therapeutic regimen. Their
results indicated that a preconception dosage of LT4 targeted
at TSH in the lower quartile of the reference range may result
in adequate maternal thyroid function up to the ﬁrst post-
conceptionevaluation.Thisobservationisinagreementwith
a retrospective study by Abalovich et al. of 53 women with
compensated hypothyroidism deﬁned as a TSH <2.5mIU/L
six months prior to conception. When the preconception
TSH was below 1.2mIU/mL, only 17.2% of women required
incrementalLT4adjustmentduringthepregnancycompared
to 50% of women having a preconception TSH between 1.2
and 2.4mIU/mL (P<0.02) [92].
These data support the logic of the premise that
women will need varying degrees of adjustment of their
prepregnancy LT4 dosage based upon the underlying cause
of their thyroid dysfunction. The best example of this
was demonstrated by Loh et al. [93] who observed that
patients with a history of thyroid cancer on doses of LT4
suﬃc i e n tt os u p p r e s sp r e c o n c e p t i o nT S Hr e q u i r e ds m a l l e r
and less frequent incremental adjustments of LT4 during
the pregnancy in order to keep TSH within the normal
range than did patients suﬀering from other causes of
hypothyroidism. Some investigators have proposed a simple
and practical formula to address this issue, suggesting that
hypothyroid women on LT4 should be advised that once
pregnant they should increase their LT4 dose by about 25%
by taking two extra doses per week of their usual daily
dose of LT4 [94]. Other than the consideration of the cost
of additional TSH measurements throughout pregnancy,
we would propose that assurance of euthyroidism during
pregnancy is best obtained by an individualized approach
to LT4 dosage adjustment based on a TSH measurement
done every 2 weeks during the ﬁrst trimester and then less
frequently thereafter as suggested by Burman [95].
TheveryrecentTHERAPYtrial(ThyroidHormoneEarly
Adjustment in Pregnancy) proposed another approach [96].
Sixtywomenwithtreatedhypothyroidismwereprospectively
randomized before their anticipated pregnancy to one of two
groups who received an increased LT4 dose of either 2 or 3
tablets per week once pregnancy was conﬁrmed. Enrollment
took place at a median 5.5 weeks of pregnancy, and patients
were followed with the measurements of TSH, TT4, and
thyroid hormone binding ratio every 2 weeks through week
20 and then once again at 30 weeks. Interestingly, despite
the early enrollment, nearly 30% of women were already
hypothyroid. The authors documented that increasing LT4
by 2 tablets per week resulted in the achievement of TSH
below 2.5mIU/L during the ﬁrst trimester in 85% of patients
without a signiﬁcantly increased risk of iatrogenic hyperthy-
roidism, which was observed in 2/25 patients compared with8 Journal of Thyroid Research
the group receiving a 3-tablet per week increment, in which
suppressed TSH was observed in 14/23 women. This study
also assessed the optimal follow-up strategy throughout the
remainderofpregnancy;documentingthat92%ofabnormal
TSH values would be detected by testing every 4 weeks.
Based upon this review of the literature, it appears clear
that there is a necessity to both update and promulgate novel
guidelines in regard to LT4 treatment during pregnancy.
In addition to the endocrine community, the guidelines
importantlyshouldreachatargetpopulationofobstetricians
and family care physicians who provide the majority of ante-
natal care. Indeed, according to one study of obstetricians
and general practitioners in Wisconsin, there is currently a
limited awareness of the 2007 Endocrine Society Guidelines
in only 11.5% of the latter population of caregivers [97].
2.6.1. A Future Research Agenda That Could Illuminate
Remaining Aspects of the Care of Pregnant Women with
Thyroid Dysfunction Might Include the Following.
(1) Determination of which strategy is most appropriate,
universal screening, or case ﬁnding, based on large
p r o s p e c t i v et r i a l sl i k eC A T Sa n dN I Ht r i a l .
(2) Assessment of the best screening strategy (TSH
versus anti-TPO Ab versus TSH + anti-TPO Ab) in
diﬀerent populations characterized by various iodine
nutritional status.
(3) ExaminingtheeﬀectsofLT4treatmentofSHandiso-
lated hypothyroxinemia on the long-term intellectual
development of oﬀspring.
(4) A study of the eﬃcacy of LT4 treatment of TPO
Ab negative women with preconception TSH levels
>2.5mIU/L.
(5) Conﬁrmation of whether the optimal preconception
target TSH concentration is 1.2mIU/L versus 1.2–
2.5mIU/L.
3. Addendum
After the acceptance of this review for the publication, the
new Guidelines of the American Thyroid Association for
the Diagnosis and Management of Thyroid Disease During
Pregnancy and Postpartum were released online [98].
The content of this review is concordant with ATA
guidelines in the following recommendations.
(1) Trimester and population speciﬁc reference ranges
for TSH should be applied. If they are not available
in the laboratory, the following reference ranges
are recommended: ﬁrst trimester, 0.1–2.5mIU/L;
secondtrimester,0.2–3.0mIU/L;thirdtrimester,0.3–
3.0mIU/L.
(2) Method-speciﬁc and trimester-speciﬁc reference
ranges of serum FT4 are required.
(3) All women with hypothyroidism and women with
subclinical hypothyroidism who are positive for
TPOAb should be treated with LT4; however due
to the lack of randomized controlled trials there is
insuﬃcient evidence to recommend for or against
universalLT4treatmentinTPOAbnegativepregnant
women with subclinical hypothyroidism.
(4) The goal of LT4 treatment is to normalize maternal
serum TSH values within the trimester-speciﬁc preg-
nancy reference range.
(5) LT4 dose should be increased by 25–30% upon
a missed menstrual cycle or positive home preg-
nancy test. This adjustment can be accomplished by
increasing LT4 by additional 2 tablets of LT4 per
week. Further adjustments should be individualized
as they are dependent on the etiology of maternal
hypothyroidism, as well as the preconception level
of TSH. Serum thyroid function tests should be
monitored closely.
(6) Hypothyroid patients (receiving LT4) who are plan-
ning pregnancy should have their dose adjusted by
their provider in order to optimize serum TSH values
to <2.5 mIU/L preconception.
Some controversial problems pointed out in this review
have been addressed by the guidelines in the following
manner.
(1) Euthyroid women (not receiving LT4) who are
TPOAb positive require monitoring for hypothy-
roidism during pregnancy.
(2) SerumTSHshouldbeevaluatedevery4weeksduring
the ﬁrst half of pregnancy and at least once between
26 and 32 weeks gestation.
(3) Isolated hypothyroxinemia should not be treated in
pregnancy,becauseofthelackofadocumentedeﬀect
of this intervention.
Some controversial problems included in this review that
remain unsolved or not addressed.
(1) There is insuﬃcient evidence to recommend for or
against screening for TPO Ab in the ﬁrst trimester
of pregnancy, or treating TPO Ab positive euthyroid
women with LT4.
(2) There is insuﬃcient evidence to recommend for or
against universal TSH screening at the ﬁrst trimester
visit.
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